Medtronic's Robotic Hernia Triumph Drives 0.65 Share Rise on 620M Volume as 153rd in Market Activity

On September 4, 2025, Medtronic (MDT) rose 0.65% with a trading volume of $0.62 billion, ranking 153rd in market activity. The company announced positive results from its Enable Hernia Repair clinical study evaluating the Hugo™ robotic-assisted surgery (RAS) system. This marks the first U.S. Investigational Device Exemption (IDE) clinical trial for robotic-assisted hernia surgery, with the system meeting primary safety and effectiveness endpoints.

The study demonstrated a 100% surgical success rate, surpassing the 85% target, and recorded 0.0% surgical site events for inguinal hernias and 2.1% for ventral hernias—well below the 30% threshold. Average hospital stays were 4.7 hours for inguinal and 6.7 hours for ventral procedures. These outcomes reinforce Medtronic’s competitive position in the $5+ billion robotic surgery market, traditionally dominated by Intuitive Surgical’s da Vinci system.

With the Hugo RAS system already available in 30+ countries, the FDA is reviewing its urology indication, expected later this fiscal year. Medtronic plans to expand approvals into hernia repair and gynecology, leveraging the system’s low complication rates and brief hospital stays to appeal to healthcare providers. The results strengthen its regulatory pathway and market potential, particularly as hernia repairs account for 1.5 million annual U.S. procedures.

Medtronic’s Hugo RAS system, designed for minimally invasive surgery, has shown strong clinical evidence, including the Expand URO study and nearly 300 independent publications. The system’s availability in the U.S. remains pending regulatory clearance, but its performance in hernia repair trials positions Medtronic to challenge existing market leaders and expand its addressable market in robotic-assisted technologies.